Drug Profile

NDL 2

Alternative Names: NDL-2

Latest Information Update: 05 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator QIMR Berghofer Medical Research Institute
Developer Kazia Therapeutics; QIMR Berghofer Medical Research Institute
Class Antineoplastics; Bicyclic peptides
Mechanism of Action B7-H1 antigen degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Breast cancer; Non-small cell lung cancer

Most Recent Events

30 Jan 2026 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical trial in Breast cancer and Non small cell lung cancer released by Kazia Therapeutics
30 Jan 2026 Kazia Therapeutics plans a first-in-human trials for NDL 2 in 2027
07 Oct 2025 Kazia Therapeutics plans IND-enabling studies in March 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com